Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $7.7 million.

  • bioAffinity Technologies' Cash & Equivalents rose 862.50% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 862.50%. This contributed to the annual value of $1.1 million for FY2024, which is 60.83% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Cash & Equivalents stood at $7.7 million, which was up 859.10% from $802,835 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Cash & Equivalents high stood at $13.5 million for Q3 2022, and its period low was $444,706 during Q1 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $2.5 million (2024), whereas its average is $3.6 million.
  • In the last 5 years, bioAffinity Technologies' Cash & Equivalents crashed by 90.35% in 2024 and then spiked by 862.50% in 2025.
  • bioAffinity Technologies' Cash & Equivalents (Quarterly) stood at $11.4 million in 2022, then plummeted by 75.28% to $2.8 million in 2023, then slumped by 60.83% to $1.1 million in 2024, then skyrocketed by 862.50% to $7.7 million in 2025.
  • Its last three reported values are $7.7 million in Q3 2025, $802,835 for Q2 2025, and $444,706 during Q1 2025.